中晚期肝细胞肝癌术后行索拉非尼治疗的疗效分析.pdfVIP

Chinese Journal of General Surgery doi:10.7659/j.issn.1005-6947.2014.07.004 /CN/abstract/abstract3947.shtml P P P P ZHUANG Lei, WEI Yonggang, YANG Jiayin, WEN Tianfu, XU Mingqing, YAN Lunan, LI Bo (Department of Hepatic Surgery, West China Hospital, Sichuan University, Chengdu 610041, China) Corresponding author: LI Bo, Email: cdlibo@ ABSTRACT Objective: To evaluate the clinical eicacy of sorafenib administration combined with liver resection in treatment of intermediate/advanced stage hepatocellular carcinoma (HCC). Methods: Data of patients with intermediate/advanced stage HCC undergoing liver resection and postoperative sorafenib therapy (observational group) from January 2010 to June 2012, along with the data of patients with intermediate/advanced stage HCC receiving surgical resection only (control group) during the same period at West China Hospital of Sichuan University were collected, for 1-to-2 matched case-control study. h e survival and tumor recurrence between the two groups were compared. Results: A total of 81 patients were included, with 27 cases in observational group and 54 cases in control group. In o